

Special Issue

Metabolism, Inflammation and Neurodegeneration: Natural Compounds as Therapeutic Agents

Message from the Guest Editor

Neurodegenerative diseases, including Alzheimer's, Parkinson's, and other age-related disorders, are major global health challenges with profound social and economic impact. These conditions are closely linked to metabolic dysfunction and chronic inflammation, both of which accelerate neuronal damage and cognitive decline. Despite decades of research, the current therapeutic options remain largely symptomatic, highlighting the urgent need for novel, disease-modifying strategies. Natural compounds offer a promising avenue for intervention, given their diverse bioactive properties, ability to target multiple molecular pathways, and favorable safety profiles. This Special Issue, titled "Metabolism, Inflammation and Neurodegeneration: Natural Compounds as Therapeutic Agents", welcomes original research and reviews exploring the mechanistic roles, preclinical efficacy, and translational potential of natural molecules in mitigating the metabolic and inflammatory processes that drive neurodegeneration. By fostering multidisciplinary contributions, we aim to advance understanding and promote innovative approaches for the effective prevention and treatment of these devastating disorders.

Guest Editor

Dr. Pedro Cisternas

Núcleo de Investigación en Nutrición y Ciencias Alimentarias (NINCAL),
Facultad de Salud y Ciencias Sociales, Universidad de las Américas,
Santiago, Chile

Deadline for manuscript submissions

25 March 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/251876

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)